Safety and PK-PD Study of Oral L-CIT in Preterm Infants With BPD±PH and NEC

Pulmonary Hypertension Clinical Trial

Official title:

A Phase I, Safety and Pharmacokinetics/Pharmacodynamics Study of Oral L-CIT Supplementation in Preterm Infants With BPD±PH and NEC

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05636397
• Other study ID #: 1000077413
• Status: Recruiting
• Phase: N/A
• Start date: November 1, 2023
• Est. completion date: March 2028

Study information

• Verified date: November 2023
• Source: The Hospital for Sick Children
• Contact: Rachana Patel, MSc, CCRP
• Phone: +1(416)-813-7654
• Email: rachana.patel[@]sickkids.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and explore the PK/PD of L-CIT supplementation in preterm infants to prevent the development of inflammatory pathways initiated by low levels of plasma CIT, specifically in preterm infants with post surgical NEC and BPD±PH.

Description:

Preterm infants are born with underdeveloped organs and immune systems, placing them at great risk for morbidity. They are more susceptible to inflammatory injury, particularly from conditions of prematurity mediated by inflammatory pathways such as bronchopulmonary dysplasia (BPD) and necrotizing enterocolitis (NEC). L-CIT, an amino acid, is the first intermediate in the urea cycle as well as a precursor to arginine and nitric oxide (NO), which promotes blood flow. It is made in the intestine and has been shown to exert vasoprotective and anti-inflammatory effects. BPD-PH and NEC are two specific inflammatory diseases of prematurity involving CIT, arginine or NO deficiencies. Evaluation of the safety and PK/PD of L-CIT supplementation for diseases involving CIT, arginine or NO deficiencies in preterm infants is important. Therefore, in this trial the investigator would like to evaluate the safety and pharmacokinetics/pharmacodynamics (PD) of L-CIT supplementation in preterm infants post surgical NEC and BPD-PH.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: March 2028
• Est. primary completion date: December 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Month to 6 Months

Eligibility

Arm 1: BPD±PH:

Inclusion Criteria:

• Born = 30 weeks at birth
• Post-menstrual age (PMA) = 34 weeks
• Echocardiographic evidence of PH for infants with BPD+PH
• On invasive or non-invasive ventilation with RSS >2.0 for >12hours/day for at least 48 hours
• Informed written consent (parents/substitute decision maker)

Exclusion Criteria:

• Congenital Heart Disease [Exceptions: small atrial septal defect (ASD), small ventricular septal defect (VSD), small patent ductus arteriosus (PDA)]
• Infants with pulmonary vein stenosis
• Concurrent sepsis with hemodynamic instability
• Infants considered likely to die within next 7 days
• Any other condition that, in the opinion of the investigator, may adversely affect the infant's ability to complete the study or its measures or pose significant risk to the infant. Arm 2: surgical NEC Inclusion Criteria
• Born = 30 weeks at birth
• Recovering from Stage IIIb NEC as per modified Bell's staging (pneumoperitoneum requiring surgery)
• Tolerating 30 ml/kg/day of enteral feeds
• On invasive or non-invasive ventilation (NIPPV/nCPAP) with RSS >2.0 for > 12hours/day for at least 48 hours, 10-14 days post surgery
• Informed written consent (parents/substitute decision maker)
• Considered medically stable by clinical team

Exclusion Criteria:

• Congenital heart disease (except small ASD, small VSD and non hsPDA)
• Pulmonary vein stenosis
• Concurrent sepsis with hemodynamic instability
• Likely to die within next 7 days
• Other condition significantly affecting pulmonary function independent of prematurity or NEC

Related Conditions & MeSH terms

• BPD - Bronchopulmonary Dysplasia
• Bronchopulmonary Dysplasia
• Hypertension, Pulmonary
• NEC
• Pulmonary Hypertension

Intervention

Dietary Supplement:
• L-Citrulline
Citrulline is a nonessential amino acid made in the small intestine, occurs naturally in the body, and is believed to help reduce inflammation.L-CIT is a part of the urea cycle, produced as a by-product along with nitric oxide (NO).

Locations

Country	Name	City	State
Canada	The Hospital For Sick Children	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
The Hospital for Sick Children

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of oral L-Citrulline administration	The number of patients with adverse events (AE) as a measure of safety and tolerability	5 years
Secondary	Association of blood pressure as one of the PD outcomes with maximum L-CIT concentration (Cmax)	Blood pressure of the study participants will be associated with PK measures of L-CIT exposure i.e. Cmax using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen. Future larger studies will then be used to examine these relationships with adequately powered studies.	5 years
Secondary	Association of stoma or nasogastric output as one of the PD outcomes with maximum L-CIT concentration (Cmax)	Stoma or nasogastric output of the study participants will be associated with PK measures of L-CIT exposure i.e. Cmax using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen. Future larger studies will then be used to examine these relationships with adequately powered studies.	5 years
Secondary	Association of stool output as one of the PD outcomes with maximum L-CIT concentration (Cmax)	Stool output from the study participants will be associated with PK measures of L-CIT exposure i.e. Cmax using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen. Future larger studies will then be used to examine these relationships with adequately powered studies.	5 years
Secondary	Association of blood pressure with the area under the concentration time curve (AUC) for L-CIT	Blood pressure of the study participants will be associated with PK measures of L-CIT exposure i.e. Area under Concentration time curve (AUC) using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen.	5 years
Secondary	Association of stoma or nasogastric output with the area under the concentration time curve (AUC) for L-CIT	Stoma or nasogastric output of the study participants will be associated with PK measures of L-CIT exposure i.e. Area under Concentration time curve (AUC) using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen.	5 years
Secondary	Association of stool output with the area under the concentration time curve (AUC) for L-CIT	Stool output from the study participants will be associated with PK measures of L-CIT exposure i.e. Area under Concentration time curve (AUC) using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen.	5 years
Secondary	Association of blood pressure with minimum L-CIT concentration (Cmin)	Blood pressure of study participants will be associated with PK measures of L-CIT exposure i.e. Cmin using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen. Future larger studies will then be used to examine these relationships with adequately powered studies.	5 years
Secondary	Association of stoma or nasogastric output with minimum L-CIT concentration (Cmin)	Stoma or nasogastric output from study participants will be associated with PK measures of L-CIT exposure i.e. Cmin using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen. Future larger studies will then be used to examine these relationships with adequately powered studies.	5 years
Secondary	Association of stool output with minimum L-CIT concentration (Cmin)	Stool output from study participants will be associated with PK measures of L-CIT exposure i.e. Cmin using univariate correlation approaches. The investigator will then attempt to construct a PK/PD model to link PK and PD measures found to be of significance during the univariate screen. Future larger studies will then be used to examine these relationships with adequately powered studies.	5 years
Secondary	Correlation between CIT and arginine levels	Correlation between changes in CIT and arginine levels with nitrite/nitrate levels	5 years
Secondary	Biomarkers of inflammation	The levels of IL-1ß, IL-6, IL-8, IL-10, TNFa will be measured in tracheal aspirates and blood plasma. The aggregated levels fo these cytokines will reflect the inflammatory status of the study participant.	5 years
Secondary	Oxidative stress	Oxidative stress (measured in tracheal aspirates and blood)	5 years
Secondary	Respiratory Score (RSS)	The respiratory severity score (RSS) is a simplified severity score consisting of the mean airway pressure (MAP) multiplied by the fraction of inspired oxygen (FiO2). This score ranges from 0 to 12, with a higher score indicating more severe lung disease.	5 years
Secondary	Desaturation index	The oxygen desaturation index (ODI) is commonly used to evaluate the severity of nocturnal hypoxemia. The ODI is defined as the number of episodes of oxygen desaturation per hour of sleep with desaturation events of >=10sec/ sampled hour.	5 years
Secondary	Changes in Blood Pressure	Changes in diastolic and systolic blood pressure prior to and during CIT treatment.	5 years
Secondary	Stoma, nasogastric or stool output	Volume of stoma, nasogastric or stool output prior to and during CIT treatment	5 years
Secondary	Ventilation	Days on mechanical ventilation, non-invasive ventilation, and supplementary oxygen	5 years
Secondary	BPD severity	Moderate to severe BPD based on the different mode of ventilatory support needed at 36 wks PMA.; No BPD = off all oxygen and positive pressure support Moderate BPD = low flow oxygen only Severe BPD= positive pressure support (high flow, CPAP, NIPPV, or ETT)	5 years
Secondary	BPD	number of days of survival free of BPD	5 years
Secondary	Pre-discharge mortality	Number of study participants who died during NICU admission.	5 years
Secondary	Postnatal steroid Use	Number of days study participants received postnatal steroids during their NICU stay.	5 years
Secondary	Bayley's scale for infant development	Bayley Scales of Infant and Toddler Development is an extensive formal developmental assessment tool for diagnosing developmental delays in early childhood. BSID is the commonly used abbreviation for Bayley Scales of Infant and Toddler Development. Bayley-III includes a motor score, and fine and gross motor subtest scores. The standardized mean motor score is 100 (SD 15), with scores lower than 85 indicating mild impairment, and lower than 70 indicating moderate or severe impairment.In this particular trial, the investigator would be looking at the correlation between the inflammatory markers (IL-1ß, IL-6, IL-8, IL-10, TNFa) and Neurodevelopmental outcomes from Bayley's scale during 18-24M follow up visit in babies received L-Citrulline during their NICU stay.	5 years